UROBEST®
Bladder Cancer Detection/Monitoring
Approved/CommercialActive
Key Facts
Indication
Bladder Cancer Detection/Monitoring
Phase
Approved/Commercial
Status
Active
Company
About Fina Biotech
Founded in 2015, Fina Biotech is a private, pre-revenue diagnostics company developing non-invasive tests for bladder cancer. Its core asset is the UROBEST® assay, which appears to be in a commercial or late-stage development phase, positioning the company to address a significant unmet need in urological oncology. Operating from Barcelona, the company is likely in a capital-intensive R&D and commercialization phase, with its success heavily dependent on clinical validation, market adoption of UROBEST®, and the progression of its pipeline projects.
View full company profileOther Bladder Cancer Detection/Monitoring Drugs
| Drug | Company | Phase |
|---|---|---|
| GALEAS Bladder (UKCA) | Nonacus | Approved |